<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • There are no suggestions because the search field is empty.

Webinar

Target Protein Degradation, Molecular Glues and RIPTAC in Oncology: Mechanisms, Models, and Strategies to Overcome Resistance

November 25 | 4:00PM JST

Targeted protein degradation and proximity-based therapeutics are expanding the oncology drug discovery landscape, with modalities such as PROTACs, molecular glues, and RIPTACs offering new ways to modulate disease-driving proteins. Translating these approaches requires a clear understanding of mechanism of action, target and effector biology, and how well preclinical findings predict responses across diverse tumor contexts.

In this webinar, experts from Crown Bioscience and ICE Bioscience will discuss complementary strategies for evaluating proximity therapeutics, from mechanistic characterization and target–effector pair validation to translational efficacy and resistance studies.

Topics will include computational modeling and experimental assay approaches, as well as the use of clinically relevant models—including patient-derived organoids and patient-derived xenografts (PDXs)—to assess target degradation, pharmacodynamic biomarkers, and antitumor activity.

The session will also explore how target expression, pathway dependency, and degradation kinetics can shape interpretation of preclinical results; how resistance may arise through changes in target biology, degradation machinery, or pathway reactivation; and how integrated models can help inform rational combination strategies, including for emerging targets such as KRAS.

What You’ll Learn:

  • How PROTACs, molecular glues, and RIPTACs work as proximity-based therapeutic modalities
  • How AI modeling, biological modules, and biophysical and cellular assays can help characterize RIPTAC mechanisms and validate target–effector pairs
  • How patient-derived organoids and PDX models can support evaluation of target degradation and antitumor activity across tumor backgrounds
  • How target expression, pathway dependency, degradation kinetics, and pharmacodynamic biomarkers inform preclinical response interpretation
  • How to investigate resistance involving target biology, degradation machinery, and pathway reactivation
  • How integrated preclinical models can support rational combination strategies and translational assessment, including for targets such as KRAS

This session is designed for discovery, translational, and preclinical oncology researchers seeking practical approaches to characterize proximity therapeutics and assess their efficacy, relevance, and potential resistance mechanisms.

*The presentation language will be in English. No subtitles are available.

**You may submit questions at any time during the session using the Q&A box. We will provide the most up-to-date answers to your questions at a later date.


About The Presenters:


rajendra-2026-circleRajendra Kumari, PhD, Executive Director, Integrated Solutions, Crown Bioscience

As Executive Director of Integrated Solutions, Rajendra leads the focus of cross-disciplinary solutions for drug discovery and development. She has over 20 years of oncology research experience with a Ph.D. in Molecular Pharmacology from the University of Leicester (UK). Prior to joining Crown Bioscience, Rajendra held an Assistant Professor position in the Division of Preclinical Oncology within the Medical School, University of Nottingham, where she developed in vitro and in vivo preclinical models, including patient-derived systems and imaging capabilities. Rajendra co-founded PRECOS Ltd., serving as COO and then following the merger with Crown Bioscience, as CSO and General Manager for Crown Bioscience UK. Rajendra became the Global Head of Scientific Communications for all platforms at Crown Bioscience Inc., working closely with R&D, multiple divisions and global departments to support the commercialization of R&D activity and capabilities. Rajendra is a member of the AACR and BACR and has authored over 40 abstracts and publications..


qing_photo_300Qing Xue (Alex), PhD International Project Manager, ICE
Bioscience

Qing is an International Project Manager at ICE Bioscience, where he
leads the development of ICE Bioscience's Induced Proximity platform,
focusing on emerging modalities including RIPTAC, PROTAC, and
molecular glue technologies. He has extensive experience in
developing biochemical, cellular, DMPK, and in vivo assays to support
proximity-based drug discovery programs. Qing holds a Ph.D. in
Biology from Tsinghua University and a Master by Research in
Biomedical Sciences from the University of Glasgow, with a strong
background in targeted protein degradation and molecular biology.

Register Now

Your privacy is important to us.
We'll never share your information.